All analyses were carried out using
JMP13 software (SAS Institute, Cary, NC, USA). Continuous and categorical data were analyzed by Wilcoxon rank sum and Pearson’s chi squared tests, respectively. Survival analyses were conducted by the Kaplan‐Meier method and log‐rank test. A Cox proportional hazards model was used to estimate hazard ratios (HR). The differential prognostic value of clinicopathological parameters was investigated through interaction tests. All
P values were two‐sided;
P < .05 was considered significant.
Shiota M., Terada N., Saito T., Yokomizo A., Kohei N., Goto T., Kawamura S., Hashimoto Y., Takahashi A., Kimura T., Tabata K., Tomida R., Hashimoto K., Sakurai T., Shimazui T., Sakamoto S., Kamiyama M., Tanaka N., Mitsuzuka K., Kato T., Narita S., Yasumoto H., Teraoka S., Kato M., Osawa T., Nagumo Y., Matsumoto H., Enokida H., Sugiyama T., Kuroiwa K., Inoue T., Mizowaki T., Kamoto T., Kojima T., Kitamura H., Sugimoto M., Nishiyama H, & Eto M. (2021). Differential prognostic factors in low‐ and high‐burden de novo metastatic hormone‐sensitive prostate cancer patients. Cancer Science, 112(4), 1524-1533.